13 results on '"Yoshikazu Tsukada"'
Search Results
2. Nationwide retrospective observational study of idiopathic dendriform pulmonary ossification: clinical features with a progressive phenotype
- Author
-
Yoshinori Hasegawa, Yasuhiko Nishioka, Shinyu Izumi, Sakae Homma, Yoshikazu Inoue, Takumi Kishimoto, Yutaro Nakamura, Takafumi Suda, Kazuya Ichikado, Takeshi Johkoh, Naoki Hamada, Koichi Hagiwara, Akira Hebisawa, Naohiko Inase, Ryoko Egashira, Kinya Abe, Masaki Okamoto, Motoyasu Kato, Yasuhiro Terasaki, Yuko Toyoda, Tomohisa Baba, Yuji Fujikura, Etsuo Fujita, Tomohiro Handa, Koko Hidaka, Takeshi Hisada, Shu Hisata, Chisato Honjo, Keisuke Miki, Masamichi Mineshita, Susumu Sakamoto, Masaaki Sano, Yoshikazu Tsukada, Mari Yamasue, and Yoshimi Bando more...
- Subjects
Medicine ,Diseases of the respiratory system ,RC705-779 - Abstract
Background Diffuse pulmonary ossification is a specific lung condition that is accompanied by underlying diseases. However, idiopathic dendriform pulmonary ossification (IDPO) is extremely rare, and the clinical features remain unclear. In this study, we aimed to report the clinical characteristics of IDPO.Methods We conducted a nationwide survey of patients with IDPO from 2017 to 2019 in Japan and evaluated the clinical, radiological, and histopathological findings of patients diagnosed with IDPO.Results Twenty-two cases of IDPO were identified. Most subjects (82%) were male, aged 22–56 years (mean (SD), 37.9 (9.1)) at diagnosis. Nearly 80% of the subjects were asymptomatic, and the condition was discovered during a medical check-up. However, 36% of the subjects showed a decline in forced vital capacity (%FVC) predicted 20 years) follow-up are required to clarify the pathogenesis and clinical findings in IDPO. more...
- Published
- 2022
- Full Text
- View/download PDF
Catalog
3. Herpes Simplex Virus Encephalitis after Recovery from Coronavirus Disease 2019: A Rare Case Report.
- Author
-
Mari Maezawa, Junichi Ochi, Natsushi Kubota, Tatsuhiko Kamoshida, Mayumi Fuji, and Yoshikazu Tsukada
- Published
- 2023
- Full Text
- View/download PDF
4. Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease
- Author
-
Kazuhiro Shimaya, Yoshikazu Tsukada, Tsukasa Okamoto, Kazuhito Saitou, Tatsuo Kawahara, Ichirou Natsume, Takaaki Yamashita, Shun Tsuyuki, Masayoshi Kobayashi, Hiroaki Saito, Yasuto Jin, Hiroyuki Sakashita, Akifumi Mochizuki, Yuri Tasaka, Yoshihiro Miyashita, Takayuki Honda, Tomoshige Chiaki, Reiko Taki, Toshiharu Tsutsui, Rie Sakakibara, Yasunari Miyazaki, Haruna Watabe, Naoki Nishiyama, and Takahiro Mitsumura more...
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Immune checkpoint inhibitors ,Pembrolizumab ,behavioral disciplines and activities ,03 medical and health sciences ,0302 clinical medicine ,Japan ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,medicine ,Humans ,Lung cancer ,Immune Checkpoint Inhibitors ,Retrospective Studies ,Response rate (survey) ,business.industry ,Interstitial lung disease ,respiratory system ,medicine.disease ,Disease control ,respiratory tract diseases ,body regions ,030104 developmental biology ,030220 oncology & carcinogenesis ,Non small cell ,Neoplasm Recurrence, Local ,Nivolumab ,Lung Diseases, Interstitial ,business - Abstract
The efficacy of immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) patients with pre-existing interstitial lung disease (ILD) is unclear.Retrospective medical data from advanced or recurrent NSCLC patients who were treated with nivolumab or pembrolizumab at ten institutions in Japan between January 2016 and September 2018 were analyzed. Eligible patients were divided into two groups according to the presence of pre-existing ILD.A total of 461 NSCLC patients were enrolled, 412 without ILD (Non-ILD group) and 49 with ILD (ILD group). The response rate (RR) and disease control rate (DCR) of the ILD group were not inferior to those of the Non-ILD group [RR: 49.0 % (24/49) vs. 30.1 % (124/412), P 0.01 and DCR: 69.4 % (34/49) vs. 51.2 % (211/412), P = 0.016, respectively]. Non-inferior outcomes were also observed with respect to progression-free survival (PFS) and overall survival (OS) (median PFS: 5.9 months vs. 3.5 months, P = 0.14 and median OS: 27.8 months vs. 25.2 months, P = 0.74 in the ILD and Non-ILD groups, respectively). Among immune-related adverse effects (irAEs), checkpoint inhibitor pneumonitis (CIP) was more frequently observed among NSCLC patients in the ILD group [30.6 % (15/49) vs. 9.5 % (39/412), P 0.01]. The frequency of irAEs other than CIP and infusion reactions was not significantly different between the ILD group and the Non-ILD group.These results suggest that the clinical outcomes of ICIs are not significantly affected by pre-existing ILD despite the increased frequency of CIP. NSCLC patients with ILD are therefore probable candidates for ICIs. more...
- Published
- 2021
- Full Text
- View/download PDF
5. Nationwide retrospective observational study of idiopathic dendriform pulmonary ossification: clinical features with a progressive phenotype
- Author
-
Yasuhiko Nishioka, Yuko Toyoda, Ryoko Egashira, Takeshi Johkoh, Yasuhiro Terasaki, Akira Hebisawa, Kinya Abe, Tomohisa Baba, Yuji Fujikura, Etsuo Fujita, Naoki Hamada, Tomohiro Handa, Yoshinori Hasegawa, Koko Hidaka, Takeshi Hisada, Shu Hisata, Chisato Honjo, Kazuya Ichikado, Yoshikazu Inoue, Shinyu Izumi, Motoyasu Kato, Takumi Kishimoto, Masaki Okamoto, Keisuke Miki, Masamichi Mineshita, Yutaro Nakamura, Susumu Sakamoto, Masaaki Sano, Yoshikazu Tsukada, Mari Yamasue, Yoshimi Bando, Sakae Homma, Koichi Hagiwara, Takafumi Suda, and Naohiko Inase more...
- Subjects
Pulmonary and Respiratory Medicine ,Male ,Phenotype ,Osteogenesis ,Vital Capacity ,Disease Progression ,Humans ,Female ,Idiopathic Pulmonary Fibrosis - Abstract
BackgroundDiffuse pulmonary ossification is a specific lung condition that is accompanied by underlying diseases. However, idiopathic dendriform pulmonary ossification (IDPO) is extremely rare, and the clinical features remain unclear. In this study, we aimed to report the clinical characteristics of IDPO.MethodsWe conducted a nationwide survey of patients with IDPO from 2017 to 2019 in Japan and evaluated the clinical, radiological, and histopathological findings of patients diagnosed with IDPO.ResultsTwenty-two cases of IDPO were identified. Most subjects (82%) were male, aged 22–56 years (mean (SD), 37.9 (9.1)) at diagnosis. Nearly 80% of the subjects were asymptomatic, and the condition was discovered during a medical check-up. However, 36% of the subjects showed a decline in forced vital capacity (%FVC) predicted )) at diagnosis. Nearly 80% of the subjects were asymptomatic, and the condition was discovered during a medical check-up. However, 36% of the subjects showed a decline in forced vital capacity (%FVC) predicted ConclusionsIDPO develops at a young age with gradually progressive phenotype. Further research and long-term (>20 years) follow-up are required to clarify the pathogenesis and clinical findings in IDPO. more...
- Published
- 2022
6. Treatment of asthma in smokers: A questionnaire survey in Japanese clinical practice
- Author
-
Susumu Isogai, Tamon Yagi, Masato Kishi, Ichiro Natsume, Tomoyuki Ogata, Reina Imase, Tsutomu Kawasaki, Tomoshige Chiaki, Motohisa Yamasaki, Sahoko Chiba, Torahiko Jinta, Yuka Mishima, Reiko Taki, Hiroaki Saito, Kimitake Tsuchiya, Jun Takagiwa, Kazuhito Saito, Naohiko Inase, Nobuo Ishiwata, Yasunari Miyazaki, Yoshikazu Tsukada, Yasuto Jin, and Yoshihiro Miyashita more...
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Muscarinic Antagonists ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Japan ,Adrenal Cortex Hormones ,immune system diseases ,Surveys and Questionnaires ,Internal medicine ,medicine ,Humans ,In patient ,030212 general & internal medicine ,Aged ,Asthma ,Smokers ,biology ,business.industry ,Medical record ,Questionnaire ,Adrenergic beta-Agonists ,Middle Aged ,Lama ,biology.organism_classification ,Former Smoker ,medicine.disease ,respiratory tract diseases ,Clinical Practice ,Clinical trial ,Prescriptions ,030228 respiratory system ,Delayed-Action Preparations ,behavior and behavior mechanisms ,Drug Therapy, Combination ,Female ,Macrolides ,business - Abstract
Cigarette smoking in patients with asthma leads to poor symptom control. As patients who are current smokers have been excluded from enrollment in many clinical trials on asthma, there are few reports on the treatment in current smokers with asthma. In this study, we aimed to assess how respiratory physicians manage asthma in current smokers in Japan.Respiratory physicians in 16 Japanese hospitals answered a questionnaire on treatment for patients with asthma between December 2014 and February 2015. Medical records were reviewed for 1756 patients with asthma.The mean patient age was 61.1 years, and 62.9% of the patients were female. A total of 102 patients (5.8%) were current smokers, and 546 patients (31.1%) were former smokers. Long-acting muscarinic antagonists (LAMA) were prescribed more frequently for current smokers with asthma than for former smokers and never smokers with asthma (10.8% vs 4.6%, p = 0.01, 10.8% vs 3.8%, p0.01). In contrast, macrolides were prescribed more frequently for former smokers and never smokers with asthma than for current smokers with asthma (7.7% vs 1.0%, p = 0.01, 6.4% vs 1.0%, p = 0.03). Triple therapy, i.e., inhaled corticosteroids, long-acting beta agonists, and LAMA concomitantly, was prescribed for current smokers with asthma more frequently than for former smokers and never smokers with asthma (9.8% vs 4.0%, p = 0.01, 9.8% vs 3.3%, p0.01).According to this survey, current smokers with asthma received more intensive therapy, including LAMA, than did former smokers with asthma. more...
- Published
- 2019
- Full Text
- View/download PDF
7. The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease
- Author
-
Takayuki Honda, Tomoshige Chiaki, Yasuto Jin, Kazuhito Saito, Tatsuo Kawahara, Yasunari Miyazaki, Tomoya Tateishi, Takaaki Yamashita, Yoshikazu Tsukada, Reiko Taki, Ichiro Natsume, Manabu Sema, Yoshihiro Miyashita, Naoki Nishiyama, and Hiroyuki Sakashita more...
- Subjects
0301 basic medicine ,Oncology ,Adult ,Male ,medicine.medical_specialty ,Lung Neoplasms ,Exacerbation ,medicine.medical_treatment ,Treatment of lung cancer ,03 medical and health sciences ,0302 clinical medicine ,Antineoplastic Agents, Immunological ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,medicine ,Humans ,Adverse effect ,Lung cancer ,Aged ,Retrospective Studies ,Aged, 80 and over ,Chemotherapy ,business.industry ,Interstitial lung disease ,Retrospective cohort study ,Hematology ,General Medicine ,respiratory system ,Middle Aged ,medicine.disease ,respiratory tract diseases ,body regions ,030104 developmental biology ,Logistic Models ,030220 oncology & carcinogenesis ,Cohort ,Surgery ,Female ,business ,Lung Diseases, Interstitial ,Tomography, X-Ray Computed - Abstract
Acute exacerbation (AE) of interstitial lung disease (ILD) is a fatal adverse event in the treatment of lung cancer patients with ILD. The value of pre-treatment radiological findings obtained by high-resolution computed tomography for the detection of anticancer treatment-related AE of ILD has not been established. Two medical record-based retrospective studies were performed. The chemotherapy cohort included 105 lung cancer patients with ILD who received chemotherapy at Tokyo Medical and Dental University between October 2008 and December 2017. The immune checkpoint inhibitor (ICI) cohort included 48 advanced non-small cell lung cancer patients with ILD treated with ICIs at nine institutions between January 2016 and September 2018. Variables were compared between AE-positive and -negative groups. Candidate variables were analyzed by multivariate logistic regression. A P value more...
- Published
- 2019
8. Treatment of Asthma in the Elderly: Questionnaire Survey in Japan
- Author
-
Reiko Taki, Yuka Mishima, Kimitake Tsuchiya, Yoshikazu Tsukada, Susumu Isogai, Jun Takagiwa, Ichiro Natsume, Tsutomu Kawasaki, Kazuhito Saito, Nobuo Ishiwata, Torahiko Jinta, Yoshihiro Miyashita, Motohisa Yamasaki, Naohiko Inase, Yasuto Jinn, Tamon Yagi, Tomoyuki Ogata, Tomoshige Chiaki, Masato Kishi, Reina Imase, and Sahoko Chiba more...
- Subjects
medicine.medical_specialty ,COPD ,business.industry ,Transdermal patch ,health care facilities, manpower, and services ,Inhaler ,Medical record ,social sciences ,Disease ,medicine.disease ,humanities ,Pulmonary function testing ,03 medical and health sciences ,0302 clinical medicine ,030228 respiratory system ,Internal medicine ,medicine ,030212 general & internal medicine ,Medical prescription ,Intensive care medicine ,business ,Asthma - Abstract
Introduction: The prevalence of asthma in the elderly has been increasing due to the aging of the global population. Appropriate treatment for asthma in the elderly is now a major issue, as the disease is often fatal and incurs high medical costs in the elderly population. There have been few recent reports on asthma treatment for the elderly in the real-world clinical settings. Objectives: This study was performed to assess how respiratory physicians manage asthma in elderly patients in clinical settings in Japan. Methods: Respiratory physicians in 16 Japanese hospitals responded to a questionnaire survey on asthma and COPD treatment between December 2014 and February 2015. The analysis was performed using data collected from medical records on 2041 asthma patients. Results: The mean patient age was 61.2 years, and 36.6% of the patients were men. In the breakdown by age, 1018 (49.9%) of the patients were elderly (≥ 65 years). Compared to the non-elderly, the elderly patients had a significantly lower BMI, greater smoking history in pack-years, and poorer pulmonary function. There were no significant differences between the elderly and non-elderly in the prescription rates of common medications such as inhaled corticosteroids, long-acting beta-agonists (LABA) administered via inhaler or transdermal patch, long-acting muscarinic antagonists, or leukotriene receptor antagonists. In contrast, mucoactive drugs (18.7% vs. 12.3%, P P P = 0.02). Conclusions: According to this survey, the prescription rates of mucoactive drugs, macrolides, and transdermal LABA were significantly higher in the elderly than in the non-elderly. more...
- Published
- 2017
- Full Text
- View/download PDF
9. Thoracoscopic Appearance and Histological Findings of Nine Cases of Pleural Malignant Mesothelioma in Relation to Clinical Findings
- Author
-
Hirotaro Miura, Minoru Hirayama, Takashi Shimizu, Yoshikazu Tsukada, Yuji Kimura, Morito Nakayama, Shigemitsu Takayama, Shinsuke Aida, Jun Takagiwa, Hisamasa Akabane, and Kazuhiko Takabe
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Oncology ,business.industry ,Internal medicine ,medicine ,business ,Gastroenterology ,PLEURAL MALIGNANT MESOTHELIOMA - Abstract
悪性胸膜中皮腫9例の胸腔鏡所見を, 組織学的所見を加え, 多発性隆起型 (隆起型) (5例) と非特異的肥厚型 (肥厚型) (4例) に分類し, 臨床所見との関連について検討した. 対象の平均年齢は66歳, 組織型は上皮型7例, 二相型2例であった. 胸腔鏡下生検により9例中6例, 67%に診断が得ちれた. 隆起型は壁側胸膜にびまん性に多発性扁平隆起を認め, 組織学的に腫瘍細胞は中皮表層を浸潤した. 肥厚型は胸膜肥厚を主体とし隆起性病変はあっても散在性で, 生検では腫瘍細胞は検出困難か (2例), 中皮下に限局し (2例), 中皮下主体の浸潤を示すと考えた. 臨床所見では, 肥厚型は全例炎症反応を伴い, 血中CRPは肥厚型で有意に高値であった (P=0.01). また, 胸水ヒアルロン酸 (μg/ml, mean±SEM) は隆起型で有意に高値であった (814±259 vs 36±8, P=0.01). この分類は臨床的に有用と考えられ報告した. more...
- Published
- 1997
- Full Text
- View/download PDF
10. [A case of pulmonary Mycobacterium shimoidei infection]
- Author
-
Satoshi, Takayama, Shinichiro, Tominaga, Yoshikazu, Tsukada, Minoru, Ohkochi, and Naohiko, Inase
- Subjects
Male ,Mycobacterium Infections ,Humans ,Tuberculosis, Pulmonary ,Aged ,Mycobacterium - Abstract
A 68 year-old male who was ex-smoker presented with fever and cough. Chest radiograph showed infiltrative shadows in both upper lung fields. A sputum smear for acid-fast bacilli was positive. But the isolate was not identified by polymerase chain reaction method. Acid-fast bacilli were cultured from sputum, but the identification was not done by DNA-DNA hybridization method. Mycobacterium shimoidei was identified by 16S ribosomal RNA sequencing with 98.42% matching. Rifampicin, ethambutol, clarithromycin, pyrazinamide, and ciprofloxacin were administered, and the symptom and abnormal shadows on chest radiography improved. And three months later from the initiation of treatment, sputum smear for acid-fast bacilli became negative. Chest CT scan four months after treatments showed decrease of infiltrative shadows. We had treated him for six months, and after that no recurrence occurred. more...
- Published
- 2006
11. [Adenosine deaminase 2 in the diagnosis of tuberculous pleuritis]
- Author
-
Naohiko, Inase, Shinichirou, Tominaga, Makito, Yasui, Yoshikazu, Tsukada, Minoru, Oukouchi, and Hirotarou, Miura
- Subjects
Adult ,Aged, 80 and over ,Male ,Adenosine Deaminase ,Tuberculosis, Pleural ,Clinical Enzyme Tests ,Middle Aged ,Sensitivity and Specificity ,DNA-Binding Proteins ,Isoenzymes ,Pleural Effusion ,Humans ,Female ,Adaptor Proteins, Signal Transducing ,Aged ,Transcription Factors - Abstract
We examined the usefulness of adenosine deaminase 2 (ADA2) in the diagnosis of tuberculous pleuritis.A hundred cases, 78 male and 22 female, with pleural effusion were examined. With regard to pleural effusion, 18 cases were transudate and 82 cases (9 tuberculous pleuritis, 27 lung cancer, 8 mesothelioma, 5 malignant diseases except lung cancer and mesothelioma, 5 benign asbestos pleurisy, 10 empyema, 10 parapneumonic effusion, one SLE, one parasitic infection, and 6 undetermined etiology) were exudates. The last 6 cases with unknown origin were excluded in this study.Pleural adenosine deaminase (ADA) was 90.4 +/- 22.4 U/l (mean +/- SD) and pleural ADA2 was 80.4 +/- 21.9 U/l in tuberculous pleuritis, both were significantly higher than those in non-tuberculous exudates (p0.001). In the diagnosis of tuberculous pleuritis, pleural ADA showed 100% sensitivity and 88% specificity, whereas pleural ADA2 showed 100% sensitivity and 91% specificity.Pleural ADA2 is useful in the diagnosis of tuberculous pleuritis, which has similar sensitivity and a little better specificity compared with pleural ADA. more...
- Published
- 2006
12. Malignant lymphoma involving the penis following malignant pleural mesothelioma
- Author
-
Jun Takagiwa, Minoru Hirayama, Morito Nakayama, Shigemitsu Takayama, Hisamasa Akabane, Shinsuke Aida, Takashi Shimizu, Yoshikazu Tsukada, Kazuhiko Takabe, Yuji Kimura, and Hirotaro Miura
- Subjects
Male ,Mesothelioma ,Pathology ,medicine.medical_specialty ,Lymphoma, B-Cell ,Biopsy ,Pleural Neoplasms ,Asbestosis ,Occupational disease ,Antineoplastic Agents ,medicine.disease_cause ,Asbestos ,Pleural disease ,Fatal Outcome ,Occupational Exposure ,Internal Medicine ,medicine ,Humans ,Penile Neoplasms ,Multiple myeloma ,Aged ,business.industry ,General Medicine ,medicine.disease ,Lymphoma ,medicine.anatomical_structure ,Carcinogens ,Radiography, Thoracic ,Neoplasm Recurrence, Local ,business ,Penis - Abstract
A 74-year-old man who had been diagnosed with malignant mesothelioma developed malignant lymphoma of B-cell origin involving the penis. He had a history of occupational exposure to asbestos as a construction worker. The association of malignant mesothelioma with lymphoma is rare, and the possibility of asbestos exposure as a common etiology is discussed. The intense stimulation of B lymphocytes and decreased T lymphocyte activity in asbestos-exposed populations may result in development of B-cell malignancies. Though the relationship between asbestos exposure and malignant mesothelioma is firmly established, the relationship between asbestos exposure and lymphoma remains to be investigated. more...
- Published
- 1998
13. Amiodarone-induced pulmonary toxicity
- Author
-
Junichi Ochi, Minoru Ohkouchi, Naohiko Inase, Yumi Miyamoto, Shinichiro Tominaga, Satoshi Takayama, Yoshikazu Tsukada, and Yuko Taniguchi
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Pathology ,Side effect ,medicine.diagnostic_test ,Pulmonary toxicity ,business.industry ,Transbronchial lung biopsy ,Mean age ,Interstitial marker ,Amiodarone ,Gastroenterology ,Ground-glass opacity ,Bronchoalveolar lavage ,Internal medicine ,medicine ,medicine.symptom ,business ,medicine.drug - Abstract
Amiodarone-induced pulmonary toxicity is a critical and potentially fatal side effect of amiodarone. Our study was designed to reveal its clinical features, including KL-6, as an interstitial marker. The medical records of eight patients (five men and three women) with amiodarone-induced pulmonary toxicity, who had been referred to our hospital, were examined. The mean age at the initiation of amiodarone was 48 years (range, 54-87 years) and mean duration of medication prior to the development of pulmonary toxicity was 18 months (range, 7-33 months). Serum KL-6 was elevated in six of the eight patients with a range of 525-2915 U/mL. Chest computed tomography (CT) findings showed non-segmental consolidation and/or ground glass opacity. Foamy macrophages were found in bronchoalveolar lavage (BAL) fluids of all examined patients and in transbronchial lung biopsy (TBLB) specimens in half of the examined patients. We concluded that serum KL-6, chest CT findings, and foamy macrophages in BAL fluids and TBLB specimens will be helpful for the diagnosis of amiodarone-induced pulmonary toxicity. more...
- Published
- 2011
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.